Geroscience hypothesis: revision 1 to 2

Revision 1

Revision 2

horizon: "2030s"

categories: ["longevity", "foundations"]

tags: ["aging", "chronic disease", "clinical trials", "regulation", "biogerontology"]

summary: "The proposition that aging is the shared upstream driver of most chronic disease, so that slowing it would delay many conditions at once rather than one at a time."

summary: "The proposition that aging is the shared upstream driver of most chronic disease, so that slowing it would delay many conditions at once instead of one at a time."

updated: "2026-07-27"

updated: "2026-10-29"

humanEvidence: "No randomised trial has shown that any intervention slows human aging; the human support is observational, from long-lived families and from an Ecuadorian Laron cohort with less cancer and diabetes but no longer life."

humanEvidence: "No randomised trial has shown that any intervention slows human aging; the human support is observational, from long-lived families and from an Ecuadorian Laron cohort with less cancer and diabetes but no longer life."

issues: ["The three-year competing-risk figure is attributed to standard estimates without a citation."]

---

"rows": [

{ "label": "Field", "value": "Geroscience" },

{ "label": "Core claim", "value": "Aging drives chronic disease" },

{ "label": "Formalised", "value": "c. 2013–2014" },

{ "label": "Formalised", "value": "c. 2013-2014" },

{ "label": "Key framework", "value": "Seven pillars of aging" },

{ "label": "Test case", "value": "TAME trial", "link": "/wiki/metformin" },

{ "label": "Status", "value": "Strong animal support, no human proof" }

}

```

**Geroscience hypothesis** is the proposition that biological aging is the principal upstream driver of most chronic disease, and that an intervention slowing aging would therefore delay cancer, cardiovascular disease, dementia, diabetes and frailty together. It reframes the target of medicine from individual pathologies to the process that makes all of them likely. The animal evidence for it is substantial. The human evidence is almost entirely absent.

**Geroscience hypothesis** is the proposition that biological aging is the principal upstream driver

of most chronic disease, and that an intervention slowing aging would therefore delay cancer,

cardiovascular disease, dementia, diabetes and frailty together. It moves the target of medicine

from individual pathologies to the process that makes all of them likely. The animal evidence for it

is substantial; the human evidence is almost entirely absent.

```keyfacts

[

  { "value": "7–8 years", "label": "Doubling time of adult mortality risk", "note": "the Gompertz relation, the field's founding observation" },

  { "value": "7-8 years", "label": "Doubling time of adult mortality risk", "note": "the Gompertz relation, the field's founding observation" },

{ "value": "7", "label": "Pillars of aging", "note": "Kennedy and colleagues, 2014" },

  { "value": "~3 years", "label": "Life expectancy at birth gained by eliminating all cancer deaths", "note": "standard competing-risk estimates; the argument for a different target" }

  { "value": "~3 years", "label": "Life expectancy at birth gained by eliminating all cancer deaths", "note": "standard competing-risk estimates; the argument for a different target" }

]

## The argument

Adult mortality risk rises roughly exponentially with age, doubling every seven to eight years, and the incidence curves for most chronic diseases follow it closely. Someone at seventy is not merely more likely to have cancer than someone at thirty; they are also more likely to have heart disease, dementia, kidney disease and osteoporosis, and to have several at once. The geroscience argument reads this covariance as evidence of a common cause.

Adult mortality risk rises roughly exponentially with age, doubling every seven to eight years, and

the incidence curves for most chronic diseases follow it closely. A seventy-year-old is more likely

than a thirty-year-old to have cancer, and also more likely to have heart disease, dementia, kidney

disease and osteoporosis, and to have several at once. The geroscience argument reads this

covariance as evidence of a common cause.

The competing-risk arithmetic supplies the practical motivation. Because an older person who avoids one fatal disease usually dies of another, eliminating any single disease adds surprisingly little to population life expectancy. Removing all cancer deaths would add roughly three years at birth by standard estimates. An intervention that shifted the entire aging trajectory, by contrast, would push every curve to the right simultaneously.

Competing-risk arithmetic supplies the practical motivation. An older person who avoids one fatal

disease usually dies of another, so eliminating any single disease adds surprisingly little to

population life expectancy: removing all cancer deaths would add roughly three years at birth by

standard estimates. An intervention that shifted the entire aging trajectory would instead push

every curve to the right at the same time.

> [!key] Why the framing changes what gets funded

> Under the disease-by-disease model, a drug that reduced frailty, improved immune response to vaccination and delayed dementia by a modest amount in one trial would have no regulatory home. Under the geroscience framing, that combination is the point.

> Under the disease-by-disease model, a drug that reduced frailty, improved immune response

> to vaccination and delayed dementia by a modest amount in one trial would have no regulatory

> home. Under the geroscience framing, that combination is the goal.

## Origins

The intellectual precursors run through Gompertz's 1825 mortality law, through James Fries's 1980 argument for [[compression-of-morbidity]], and through the demonstration in the 1980s and 1990s that single-gene mutations could extend lifespan in nematodes and mice while delaying multiple age-related pathologies, of which

The intellectual precursors include Gompertz's 1825 mortality law, James Fries's 1980 argument for

[[cynthia-kenyon|the 1993 daf-2 result in nematodes]] is the best known.

[[compression-of-morbidity]], and the demonstration in the 1980s and 1990s that single-gene

mutations could extend lifespan in nematodes and mice while delaying multiple age-related

pathologies. The best known of these is [[cynthia-kenyon|the 1993 daf-2 result in nematodes]].

The modern formulation dates to the early 2010s. A trans-NIH Geroscience Interest Group formed in 2012 and convened a summit the following year, and a 2014 paper by Brian Kennedy and colleagues set out seven "pillars of aging" as a shared conceptual base: adaptation to stress, epigenetics, inflammation, macromolecular damage, metabolism, proteostasis, and stem cells and regeneration.[^kennedy2014] The pillars overlap heavily with the [[hallmarks-of-aging]] and were framed more explicitly around translation, grouping mechanisms such as [[proteostasis]] failure, [[inflammaging|chronic inflammation]] and [[stem-cell-exhaustion]] as shared substrates rather than as separate research areas. In parallel, S. Jay Olshansky and colleagues argued the economic case that became the [[longevity-dividend]].[^olshansky2006] Institutions built around the framing, notably the [[buck-institute]], predate the label by more than a decade.

The modern formulation dates to the early 2010s. A trans-NIH Geroscience Interest Group formed in

2012 and convened a summit the following year, and a 2014 paper by Brian Kennedy and colleagues set

out seven "pillars of aging" as a shared conceptual base: adaptation to stress, epigenetics,

inflammation, macromolecular damage, metabolism, proteostasis, and stem cells and

regeneration.[^kennedy2014] The pillars overlap heavily with the [[hallmarks-of-aging]] but were

framed more explicitly around translation. They group mechanisms such as [[proteostasis]] failure,

[[inflammaging|chronic inflammation]] and [[stem-cell-exhaustion]] as shared substrates instead of

separate research areas. In parallel, S. Jay Olshansky and colleagues made the economic case that

became the [[longevity-dividend]].[^olshansky2006] Institutions built around the framing, such as

the [[buck-institute]], predate the label by more than a decade.

## Evidence in animals

The strongest support comes from interventions that extend lifespan in mammals and delay multiple pathologies at once. [[caloric-restriction]] does this across many species. [[rapamycin]] extends lifespan in genetically heterogeneous mice even when started late in life,[^harrison2009] and treated mice show delayed decline in immune and cognitive function. Growth-hormone-pathway mutants such as Ames dwarf and growth hormone receptor knockout mice live longer and develop tumours later. [[senolytics]] improve function across several tissues in aged mice.

The strongest support comes from interventions that extend lifespan in mammals and delay multiple

pathologies at once. [[caloric-restriction]] does this across many species. [[rapamycin]] extends

lifespan in genetically heterogeneous mice even when started late in life,[^harrison2009] and

treated mice show delayed decline in immune and cognitive function. Growth-hormone-pathway mutants

such as Ames dwarf and growth hormone receptor knockout mice live longer and develop tumours later.

[[senolytics]] improve function across several tissues in aged mice.

Crucially, these interventions do not act on one disease. A rapamycin-fed mouse is not protected against cancer alone; decline is delayed in several tissues at once, although not uniformly, and some age-related pathologies proceed unchanged. That multi-system pattern is what the hypothesis predicts, and it is why the animal literature is treated as strong evidence.

None of these interventions acts on a single disease. A rapamycin-fed mouse is not protected against

cancer alone: decline is delayed in several tissues at once, although not uniformly, and some

age-related pathologies proceed unchanged. The hypothesis predicts this multi-system pattern, which is why the animal literature is

treated as strong evidence.

## Evidence in humans

Human support is indirect. People who reach extreme old age tend to compress their period of illness rather than extend it, developing major disease later and dying after a shorter terminal decline than people who die in their seventies.[^andersen2012] Long-lived families show delayed onset across several unrelated conditions. Common variants associated with longevity are few and of small effect, but the familial clustering is real.

Human support is indirect. People who reach extreme old age tend to compress their period of

illness: they develop major disease later and die after a shorter terminal decline than people who

die in their seventies.[^andersen2012] Long-lived families show delayed onset across several

unrelated conditions. Common variants associated with longevity are few and of small effect, but the

familial clustering is real.

A revealing natural experiment is Laron syndrome, in which growth hormone receptor signalling is absent. An Ecuadorian cohort followed for decades showed near-absence of cancer and of type 2 diabetes, matching the mouse mutants, without a corresponding increase in lifespan; deaths came instead from accidents, alcohol-related causes and cardiovascular disease.[^guevara2011] The result supports the disease-delay half of the hypothesis and complicates the lifespan half.

Laron syndrome, in which growth hormone receptor signalling is absent, offers a natural experiment.

An Ecuadorian cohort followed for decades showed near-absence of cancer and of type 2 diabetes,

matching the mouse mutants, without a corresponding increase in lifespan; deaths came instead from

accidents, alcohol-related causes and cardiovascular disease.[^guevara2011] The result supports the

disease-delay half of the hypothesis and complicates the lifespan half.

What does not exist is a randomised human trial showing that any intervention slows aging. [[exercise-and-aging|Exercise]] is the best-evidenced practice for delaying multiple age-related outcomes, and it is not a drug. [[metformin]], [[nad-precursors]] and other candidates have not demonstrated the effect in controlled human studies.

No randomised human trial has shown that any intervention slows aging.

[[exercise-and-aging|Exercise]] is the best-evidenced practice for delaying multiple age-related

outcomes, and it is not a drug. [[metformin]], [[nad-precursors]] and other candidates have not

demonstrated the effect in controlled human studies.

## Objections

**The framework may be a taxonomy, not a theory.** Listing pillars or hallmarks does not establish that they share a driver, and interventions that hit one hallmark do not reliably move the others. Clearing senescent cells does not repair [[mitochondrial-dysfunction|mitochondrial damage]]; restoring [[autophagy|autophagic]] flux does not lengthen [[telomeres-and-telomerase|telomeres]]. Critics argue that "aging" names a correlated bundle of processes rather than a single manipulable variable, and that the appeal of the framing outruns its explanatory content.

**The framework may be a taxonomy rather than a theory.** Listing pillars or hallmarks does not

establish that they share a driver, and interventions that hit one hallmark do not reliably move the

others. Clearing senescent cells does not repair [[mitochondrial-dysfunction|mitochondrial damage]];

restoring [[autophagy|autophagic]] flux does not lengthen [[telomeres-and-telomerase|telomeres]].

Critics argue that "aging" names a correlated bundle of processes instead of a single manipulable

variable, and that the appeal of the framing outruns its explanatory content.

**Mouse results translate badly.** The mammalian aging literature has produced few candidates that survive contact with human trials. Senolytic drugs are the clearest current example: dramatic mouse data followed by human results that have been modest or null.

**Mouse results translate badly.** The mammalian aging literature has produced few candidates that

hold up in human trials. Senolytic drugs are the clearest current example: dramatic mouse data were

followed by human results that have been modest or null.

**Trade-offs are underweighted.** Rapamycin is an immunosuppressant at transplant doses. Growth-hormone pathway suppression costs stature and, in mice, some cognitive and wound-healing capacity. An intervention that slows aging by slowing everything may not be one people want.

**Trade-offs are underweighted.** Rapamycin is an immunosuppressant at transplant doses. Suppressing

the growth-hormone pathway costs stature and, in mice, some cognitive and wound-healing capacity. An

intervention that slows aging by slowing everything may not be one people want.

**Success might expand morbidity rather than compress it.** The empirical record in high-income countries over recent decades is closer to expansion of the years lived with disease than to compression, which is a point against the optimistic reading of what delaying aging would deliver.

**Success might expand morbidity rather than compress it.** Over recent decades the empirical record

in high-income countries is closer to an expansion of the years lived with disease than to

compression, which counts against the optimistic reading of what delaying aging would deliver.

## Regulatory implications

No major regulator recognises aging as an indication, so a drug cannot be approved to treat it. The exception is veterinary: the US Food and Drug Administration's animal-drug centre will consider lifespan extension itself as an indication, which is the route [[loyal]] is taking in dogs, and nothing about that pathway carries over to human approval. The workaround pursued by [[nir-barzilai]] and colleagues is TAME, designed less as a test of the drug itself than as a template: a trial whose primary endpoint is time to the first occurrence of any of several age-related diseases or death, which if accepted would establish that a multi-disease endpoint can support a label. It has never been fully funded, in part because a generic drug offers no sponsor a return, and it has not enrolled.

No major regulator recognises aging as an indication, so a drug cannot be approved to treat it. The

exception is veterinary: the US Food and Drug Administration's animal-drug centre will consider

lifespan extension itself as an indication. [[loyal]] is taking that route in dogs, and nothing

about the pathway carries over to human approval. The workaround pursued by [[nir-barzilai]] and

colleagues is TAME, designed less as a test of the drug itself than as a template. Its primary

endpoint is time to the first occurrence of any of several age-related diseases or death; if

regulators accepted it, the trial would establish that a multi-disease endpoint can support a label.

TAME has never been fully funded, in part because a generic drug offers no sponsor a return, and it

has not enrolled.

The alternative route is a validated surrogate. Without one, geroscience trials are long and expensive, which is the problem set out under [[aging-biomarkers]]. The field's difficulty is that its two paths to the clinic each depend on the other being easy.

The alternative route is a validated surrogate. Without one, geroscience trials are long and

expensive, the problem set out under [[aging-biomarkers]]. Each of the field's two paths to the

clinic would be easier if the other were already open.

## What would settle it

A clean test would take a single intervention, apply it to a population in a randomised trial, and show delayed onset across several unrelated age-related conditions relative to placebo, with functional measures moving in the same direction. Nothing of that design has reported. Intermediate evidence may come from companion dogs, whose lifespans are short enough to observe and whose environment resembles their owners'; work of this kind has faced funding instability. Until such a result exists, geroscience remains a well-motivated hypothesis with a strong animal literature and no human demonstration, and claims about [[longevity-escape-velocity]] or [[maximum-human-lifespan]] that assume it has been proven are assuming the conclusion.

A clean test would take a single intervention, apply it to a population in a randomised trial, and

show delayed onset across several unrelated age-related conditions relative to placebo, with

functional measures moving in the same direction. No trial of that design has reported. Intermediate

evidence may come from companion dogs, whose lifespans are short enough to observe and whose

environment resembles their owners'; work of this kind has faced funding instability. Until such a

result exists, geroscience remains a well-motivated hypothesis with a strong animal literature and

no human demonstration. Claims about [[longevity-escape-velocity]] or [[maximum-human-lifespan]]

that treat it as proven are assuming the conclusion.

## See also